Form 8.3

Rathbones Group plc filed a Rule 8.3 disclosure for an opening position/dealing dated 15/07/2026 and disclosed positions as of that latest practicable date. It reported holding 11,109,700 5p ordinary shares (5.03%) in Advanced Medical Solutions Group plc and separately sold 19,655 shares at 279p per unit. No supplemental open-positions form was attached and no options/derivative positions were reported in the tables provided.

Analysis

This reads more like a market-structure breadcrumb than a fundamentals signal. A 5%+ holder making a small trim is only meaningful if there is already an active bid process; otherwise it is just portfolio rebalancing and carries little independent valuation content. The only immediate effect is that event-driven holders may treat the name as more tightly held, which can make the stock more sensitive to incremental flow and widen the offer/holding-period spread.

The second-order issue is not the sale itself but what it implies for takeover-arb positioning: if there is a live corporate action, a visible reduction by a relevant shareholder can slightly raise the probability that the register is less supportive of a deal, increasing the risk of a wider spread or a slower path to acceptance. That matters most over the next 1-3 months as more Rule 8.x disclosures land; absent those, the disclosure is basically noise. On a 6-18 month horizon, the only durable signal would be if additional holders start trimming and the company is forced into strategic review or restructuring, but we do not have evidence of that here.

Contrarian take: the consensus may be over-reading any Rule 8.3 print as a ‘smart money’ signal. In many cases these filings are compliance artifacts from custodial rebalancing, not a view on fair value. The falsifier is simple: if no further offer-related disclosures, scheme documents, or bid guidance emerge within weeks, this should be ignored and the tape will likely mean-revert.

Key Decisions for Investors

• No new position in RTBBF on this disclosure alone; treat as low-signal compliance flow unless a formal offer or scheme announcement follows within 1-3 weeks.
• If already long RTBBF in an event-driven book, keep exposure small and tighten risk: reduce on any spread widening without fresh offer disclosures, as the disclosure can invite de-risking by arbitrage funds.
• Set an alert for additional UK Takeover Code filings on RTBBF over the next 30 days; the trade becomes actionable only if there is follow-on accumulation, irrevocables, or a revised deal timetable.
• Relative-value watch: if RTBBF rallies on rumor without confirming disclosures, consider fading the move versus a UK small-cap healthcare basket, since the current print does not improve intrinsic value.
• Do not express a view in CGAC based on this filing; there is no visible channel from this disclosure to CGAC fundamentals or catalyst timing.